Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

NCT06660511 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG: Disitamab Vedotin in Combination With Anlotinib Hydrochloride

Sponsor

Second Xiangya Hospital of Central South University